Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2026

Conditions

Biliary Tract CancerCandonilimabClaudin 18.2

Interventions

DRUG

cardonilizumab

cardonilizumab:PD1 and CTLA-4 bispecific antibody

DRUG

LM-302

LM-302 :ClAUDIN 18.2-ADC

Trial Locations (1)

RECRUITING

Zhongshan hospital, Fudan University, Shanghai

All Listed Sponsors

lead

Shanghai Zhongshan Hospital

OTHER